Monitor for any subsequent Form 4 filings that may indicate insider buying or selling activity, which could provide signals about management's view of the company's prospects.
Price Chart
Executive Summary
Freda C. Lewis-Hall filed a Form 3 initial statement of beneficial ownership after becoming a director of Helus Pharma Inc., disclosing 100,000 common shares held directly, options to buy 25,000 shares at $5.99 expiring in 2035 (held by Intelmed, LLC), and 25,000 restricted share units vesting in November 2026. This is a routine insider filing with no material financial impact.
Key Facts
- Freda C. Lewis-Hall filed Form 3 as a new reporting person (director) of Helus Pharma Inc.
- Directly holds 100,000 common shares.
- Holds options to buy 25,000 common shares at $5.99 per share, expiring October 1, 2035, vesting quarterly over two years starting December 31, 2025.
- Holds 25,000 restricted share units vesting on November 20, 2026.
- Options are held indirectly through Intelmed, LLC, which is owned and controlled by the reporting person.
Financial Impact
No financial impact; the filing is a routine initial beneficial ownership disclosure.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0000912282-26-001390 |
| Document: 0000912282-26-001390-index.html | 0000912282-26-001390 |
| Document: 0000912282-26-001390.txt | 0000912282-26-001390 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $10.66 | awaiting T+20 | awaiting T+20 | $10.52 (−1.27%) |
Oct 26, 2026 1d ago | 3 | $10.36 | awaiting T+20 | awaiting T+20 | $10.52 (+1.54%) |
Oct 26, 2026 1d ago | 3 | $10.36 | awaiting T+20 | awaiting T+20 | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | awaiting T+20 | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | awaiting T+20 | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | awaiting T+20 | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | awaiting T+20 | $10.52 (+1.54%) |
Oct 21, 2026 6d ago | 6-K | $10.50 | awaiting T+20 | awaiting T+20 | $10.52 (+0.19%) |
Oct 15, 2026 12d ago | 6-K | $11.05 | awaiting T+20 | awaiting T+20 | $10.52 (−4.80%) |
Oct 15, 2026 13d ago | Press Release | $11.05 | awaiting T+20 | awaiting T+20 | $10.52 (−4.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers